A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

GSK chief scientific officer Tony Wood stated: “Collaboration is at the heart of scientific progress and is fundamental to ...

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

The upgraded manufacturing campus will be equipped to crank out commercial drugs and vaccines plus house an R&D pilot plant to manufacture medicines for clinical trials. GSK plans to add about 200 ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day; 1 in 3 people will get s ...

GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...

GSK is delivering consistent financial performance. Looking to the end of this year and beyond, we're even more confident that the progress we're making in portfolio development and in R&D support ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...